Incyte Corporation vs Lufax Holding Ltd — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while Lufax Holding Ltd trades at $1.4 (market cap $2.41B). The key difference: Incyte Corporation is far larger — about 9.6× Lufax Holding Ltd's market cap, and Incyte Corporation is trading nearer its 52-week high, Lufax Holding Ltd nearer its low. Which is the better fit depends on your goals.
| INCY | LU | |
|---|---|---|
Market Cap | $23.11B | $2.41B |
Sector | Health | Technology |
52-Week High | $118.52 | $4.40 |
52-Week Low | $67.38 | $1.23 |
Enterprise Value | $19.13B | — |
Trailing returns across standard periods
Latest headlines on both assets
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →